Two women, aged 81 and 61, became haemorrhagic after surgery. Their previous surgeries were uneventful with no unexpected bleeding observed. Blood tests prior to the current surgeries indicated normal values including those related to coagulation. There were no problems with the current surgeries prior to leaving the operating room. At 3 hours after the surgery, the 81-year-old patient had an o...

Antibodies to factor XIII have not been Antisera to ‘yG2, i G3, ‘yG4, ‘yA, ‘yM, previously characterized in detail. An ac‘yD, ‘yE, and k light-chains had no detectquired inhibitor to factor XIII, which develable effect. Preparative zone electrooped in a patient following thrombectomy phoresis revealed the inhibitor to be in for a femoral artery occlusion, has been the cathodal portion of the ga...

Antibodies to factor XIII have not been Antisera to ‘yG2, i G3, ‘yG4, ‘yA, ‘yM, previously characterized in detail. An ac‘yD, ‘yE, and k light-chains had no detectquired inhibitor to factor XIII, which develable effect. Preparative zone electrooped in a patient following thrombectomy phoresis revealed the inhibitor to be in for a femoral artery occlusion, has been the cathodal portion of the ga...

The authors report a new case of congenital deficiency of fibrin stabilizing factor. The defect is transmitted as an autosomal recessive trait. The earliest symptom is umbilical bleeding when the cord separates. The diagnosis is confirmed by the rapid dispersion of the clot in urea 5 M or monochloroacetic acid.

Objective This study aims to give information about the relationship between different types of factor deficiencies and maternal/obstetric outcomes. Methods We retrospectively reviewed the medical records of eight women with factor deficiency disorders. The demographic and clinical features of the patients after their last pregnancies were registered retrospectively. Results There were 29 pregn...

Congenital factor XIII (FXIII) deficiency is a rare, autosomal-recessive disorder, with most patients having an A-subunit (FXIII-A) deficiency. Patients experience life-threatening bleeds, impaired wound healing, and spontaneous abortions. In many countries, only plasma or cryoprecipitate treatments are available, but these carry a risk for allergic reactions and infection with blood-borne path...

Blood Transfus 2015; 13: 324-7 DOI 10.2450/2014.0024-14 © SIMTI Servizi Srl Introduction Plasma factor XIII (FXIII) is a pro-enzyme (composed of 2α2β subunits), activated to XIIIa by calcium and thrombin in the final step of the coagulation cascade. FXIII stabilises the clot during the process of haemostasis by catalysing the cross-linking of fibrin, platelet membrane and matrix proteins. Moreo...

A 26-year-old male presented with claw toes and Factor XIII deficiency. Correction for his deformity was undertaken. Pre, intra and post-operative transfusions of plasma and blood prevented any haemorrhagic complications.